These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18307022)

  • 1. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.
    Rizell M; Andersson M; Cahlin C; Hafström L; Olausson M; Lindnér P
    Int J Clin Oncol; 2008 Feb; 13(1):66-70. PubMed ID: 18307022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD
    Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hepatocellular and cholangiocellular carcinoma.
    Murakami T; Kim T; Tomoda K; Narumi Y; Sakon M; Wakasa K; Nakamura H
    Radiat Med; 1997; 15(4):243-6. PubMed ID: 9311042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
    Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
    J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
    Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
    Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
    Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
    Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
    Patkowski W; Stankiewicz R; Grąt M; Krasnodębski M; Kornasiewicz O; Krawczyk M
    Transplant Proc; 2014 Oct; 46(8):2774-6. PubMed ID: 25380915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years.
    Kim DK; Kim BR; Jeong JS; Baek YH
    World J Gastroenterol; 2019 Feb; 25(5):608-621. PubMed ID: 30774275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary Liver Cancers - Hepatocellular Carcinoma and Cholangiocarcinoma].
    Soysal SD; Kollmar O
    Ther Umsch; 2021; 78(10):585-588. PubMed ID: 34844438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.
    Decaens T; Luciani A; Itti E; Hulin A; Roudot-Thoraval F; Laurent A; Zafrani ES; Mallat A; Duvoux C
    Dig Liver Dis; 2012 Jul; 44(7):610-6. PubMed ID: 22459565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of combined hepatocellular and cholangiocarcinoma.
    Kassahun WT; Hauss J
    Int J Clin Pract; 2008 Aug; 62(8):1271-8. PubMed ID: 18284443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma.
    Park YH; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Namgoong JM; Park CS; Park HW; Kang SH; Jung BH; Lee SG
    Transplant Proc; 2013 Oct; 45(8):3038-40. PubMed ID: 24157031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and prospects of biomarkers in primary liver cancer (Review).
    Gao YX; Yang TW; Yin JM; Yang PX; Kou BX; Chai MY; Liu XN; Chen DX
    Int J Oncol; 2020 Jul; 57(1):54-66. PubMed ID: 32236573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.
    Sapisochin G; de Lope CR; Gastaca M; de Urbina JO; López-Andujar R; Palacios F; Ramos E; Fabregat J; Castroagudín JF; Varo E; Pons JA; Parrilla P; González-Diéguez ML; Rodriguez M; Otero A; Vazquez MA; Zozaya G; Herrero JI; Antolin GS; Perez B; Ciria R; Rufian S; Fundora Y; Ferron JA; Guiberteau A; Blanco G; Varona MA; Barrera MA; Suarez MA; Santoyo J; Bruix J; Charco R
    Ann Surg; 2014 May; 259(5):944-52. PubMed ID: 24441817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.
    Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M
    Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.